Appropriate use of antifungals: impact of an antifungal stewardship program on the clinical outcome of candidaemia in a French University Hospital.
Antifungal stewardship
Candidaemia
Fungal infections
Prescribing practice
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
18
09
2018
accepted:
27
12
2018
pubmed:
27
2
2019
medline:
31
8
2019
entrez:
27
2
2019
Statut:
ppublish
Résumé
The objective of this study was to compare clinical outcomes of patients with candidaemia before and after implementation of an antifungal stewardship program (AFSP). This study included all consecutive cases of candidaemia identified from January 2012 to December 2015 in a French University Hospital. Data were collected retrospectively for a period of 2 years before implementation of the AFSP, and prospectively for 2 years after. All cases were reviewed by a multidisciplinary panel of experts including infectiologists, a microbiologist and pharmacists to have a complete follow-up of patients. 33 and 37 patients were finally included in the first and second period, respectively. The sites of entry of the candidaemia cases studied were as follows: intraabdominal in 29 cases (41.4%), central venous catheter 21 (30.0%), other or unknown: 20 (28.6%). Infectiologist consultations increased from 36.4 to 86.5% between the two periods with a significative impact on daily blood cultures which were more frequently performed in the second period (p = 0.04), and the use of echinocandins which was more frequent in the second period (97.1% of cases vs 78.8%, p = 0.03). The 3-month mortality rate declined from 36.4% in the first period to 27.0% in the second period (p = 0.4). Despite the insufficient number of candidaemia cases and the presence of other unmodifiable risk factors of mortality which did not allow us to show a significant effect on the 3-month mortality, AFSP had a significant effect on daily blood cultures and echinocandin use as first-line therapy.
Identifiants
pubmed: 30806974
doi: 10.1007/s15010-018-01264-4
pii: 10.1007/s15010-018-01264-4
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-440Références
Am J Med. 2002 Oct 15;113(6):480-5
pubmed: 12427497
Clin Infect Dis. 2004 Aug 1;39(3):309-17
pubmed: 15306996
J Clin Microbiol. 2005 Apr;43(4):1829-35
pubmed: 15815004
Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5
pubmed: 16127033
Eur J Clin Microbiol Infect Dis. 2006 Jul;25(7):419-25
pubmed: 16773391
Clin Microbiol Rev. 2007 Jan;20(1):133-63
pubmed: 17223626
Infect Control Hosp Epidemiol. 2010 Jul;31(7):722-7
pubmed: 20497042
Clin Microbiol Infect. 2011 Sep;17 Suppl 5:1-12
pubmed: 21884296
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
pubmed: 23137135
Pharmacotherapy. 2013 Feb;33(2):137-43
pubmed: 23355283
J Antimicrob Chemother. 2014 Jul;69(7):1993-9
pubmed: 24659750
Emerg Infect Dis. 2014 Jul;20(7):1149-55
pubmed: 24960557
Clin Microbiol Infect. 2014 Oct;20(10):954-62
pubmed: 25294340
J Antimicrob Chemother. 2015;70(6):1908-11
pubmed: 25722302
Lancet Infect Dis. 2015 Dec;15(12):1438-49
pubmed: 26411518
N Engl J Med. 2015 Oct 8;373(15):1445-56
pubmed: 26444731
J Antimicrob Chemother. 2016 Nov;71(suppl 2):ii5-ii12
pubmed: 27880664
J Antimicrob Chemother. 2016 Nov;71(suppl 2):ii37-ii42
pubmed: 27880668
J Antimicrob Chemother. 2016 Nov;71(suppl 2):ii43-ii44
pubmed: 27880669
Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543
pubmed: 28178770
Ther Adv Infect Dis. 2018 Jan;5(1):3-10
pubmed: 29344355